Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q2 2023
Holdings as of Jun 30, 2023, filed Aug 14, 2023. Long positions only; changes compare share counts with Q1 2023.
- Positions
- 55
- +3 vs. Q1 2023
- Portfolio value
- $277.1M
- +$12.8M (+4.8%) vs. Q1 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| KYNBKyntra Bio, Inc. | COM | 36,500 | $98.5K | <0.1% | +10,000+37.7% | Added | History |
| MRSNMersana Therapeutics, Inc. | COM | 61,250 | $201.5K | 0.1% | +61,250 | New | History |
| VNDAVanda Pharmaceuticals Inc. | COM | 31,000 | $204.3K | 0.1% | +18,500+148.0% | Added | History |
| REPLReplimune Group, Inc. | COM | 10,865 | $252.3K | 0.1% | +10,865 | New | History |
| Rain Oncology Inc.75082Q105 | COM | 325,000 | $390.0K | 0.1% | +75,000+30.0% | Added | – |
| ROIVRoivant Sciences Ltd. | SHS | 64,000 | $645.1K | 0.2% | +64,000 | New | History |
| PTCTPTC Therapeutics, Inc. | COM | 16,675 | $678.2K | 0.2% | +16,675 | New | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 100,000 | $704.0K | 0.3% | −900,000−90.0% | Reduced | History |
| Avidity Biosciences, Inc.05370A108 | COM | 65,000 | $720.9K | 0.3% | −60,000−48.0% | Reduced | – |
| BBIOBridgeBio Pharma, Inc. | COM | 42,000 | $722.4K | 0.3% | +17,000+68.0% | Added | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 27,578 | $723.1K | 0.3% | 00.0% | Unchanged | History |
| INBXInhibrx Biosciences, Inc. | COM | 35,000 | $908.6K | 0.3% | +35,000 | New | History |
| MORFMorphic Holding, Inc. | COM | 20,000 | $1.15M | 0.4% | +20,000 | New | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 200,000 | $1.41M | 0.5% | −75,000−27.3% | Reduced | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 75,000 | $1.49M | 0.5% | +75,000 | New | History |
| RCUSArcus Biosciences, Inc. | COM | 75,000 | $1.52M | 0.5% | 00.0% | Unchanged | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 250,000 | $1.71M | 0.6% | +100,000+66.7% | Added | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 280,981 | $1.76M | 0.6% | +280,981 | New | History |
| IMGNImmunoGen, Inc. | COM | 100,000 | $1.89M | 0.7% | −24,977−20.0% | Reduced | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 412,699 | $1.93M | 0.7% | +62,699+17.9% | Added | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 154,250 | $2.21M | 0.8% | +154,250 | New | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 110,000 | $2.33M | 0.8% | +110,000 | New | History |
| KRYSKrystal Biotech, Inc. | COM | 20,000 | $2.35M | 0.8% | +20,000 | New | History |
| QUREuniQure N.V. | SHS | 215,000 | $2.46M | 0.9% | −160,000−42.7% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 300,173 | $2.50M | 0.9% | −149,827−33.3% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 200,000 | $2.51M | 0.9% | −275,000−57.9% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 150,000 | $2.71M | 1.0% | +70,000+87.5% | Added | History |
| KRTXKaruna Therapeutics, Inc. | COM | 12,500 | $2.71M | 1.0% | −5,000−28.6% | Reduced | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 100,000 | $2.82M | 1.0% | +100,000 | New | History |
| JBIOJade Biosciences, Inc. | COM | 201,197 | $3.45M | 1.2% | +1,197+0.6% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 347,432 | $3.57M | 1.3% | +147,432+73.7% | Added | History |
| VIRVir Biotechnology, Inc. | COM | 150,000 | $3.68M | 1.3% | +150,000 | New | History |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 238,225 | $3.92M | 1.4% | −11,775−4.7% | Reduced | History |
| ONCBeOne Medicines Ltd. | ADR | 22,500 | $4.01M | 1.4% | +22,500 | New | History |
| INCYIncyte Corp | COM | 65,000 | $4.05M | 1.5% | −10,000−13.3% | Reduced | History |
| BMEABiomea Fusion, Inc. | COM | 190,000 | $4.17M | 1.5% | +70,000+58.3% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 240,000 | $5.71M | 2.1% | +65,000+37.1% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 225,000 | $6.21M | 2.2% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 575,000 | $6.81M | 2.5% | +25,000+4.5% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 185,000 | $7.12M | 2.6% | −15,000−7.5% | Reduced | History |
| MRTXMirati Therapeutics, Inc. | COM | 200,000 | $7.23M | 2.6% | +60,000+42.9% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 350,000 | $7.33M | 2.6% | +25,000+7.7% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 110,000 | $7.90M | 2.9% | −115,000−51.1% | Reduced | History |
| RETAReata Pharmaceuticals Inc | CL A | 85,000 | $8.67M | 3.1% | +15,000+21.4% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 100,000 | $8.93M | 3.2% | −10,000−9.1% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 85,000 | $9.73M | 3.5% | +25,000+41.7% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 650,000 | $10.5M | 3.8% | +50,000+8.3% | Added | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 550,000 | $11.9M | 4.3% | +75,000+15.8% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 55,000 | $12.7M | 4.6% | +25,000+83.3% | Added | History |
| RVNCRevance Therapeutics, Inc. | COM | 525,000 | $13.3M | 4.8% | +275,000+110.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 280,000 | $14.0M | 5.0% | +55,000+24.4% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 180,000 | $16.4M | 5.9% | +15,380+9.3% | Added | History |
| AKROAkero Therapeutics, Inc. | COM | 360,000 | $16.8M | 6.1% | +85,000+30.9% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 330,000 | $16.8M | 6.1% | +135,000+69.2% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 825,000 | $20.5M | 7.4% | −275,000−25.0% | Reduced | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | – | $25.0M |
| BTAIQBioXcel Therapeutics, Inc. | COM | – | $865.8K |
Sold out since Q1 2023 (11)
Positions held at the end of Q1 2023 that are gone from this filing.
| Security | Class | Shares in Q1 2023 | Value in Q1 2023 | % of portfolio in Q1 2023 | History |
|---|---|---|---|---|---|
| CTICCti Biopharma Corp | COM | 2,000,000 | $8.40M | 3.2% | History |
| PFEPfizer Inc | Stock | 200,000 | $8.16M | 3.1% | History |
| JNJJohnson & Johnson | Stock | 50,000 | $7.75M | 2.9% | History |
| ISEEIVERIC bio, Inc. | COM | 175,000 | $4.26M | 1.6% | History |
| ACRSAclaris Therapeutics, Inc. | COM | 425,000 | $3.44M | 1.3% | History |
| ETNB89bio, Inc. | COM | 200,000 | $3.05M | 1.2% | History |
| IRONDisc Medicine, Inc. | COM | 100,000 | $2.12M | 0.8% | History |
| RXDXPrometheus Biosciences, Inc. | COM | 15,000 | $1.61M | 0.6% | History |
| GERNGeron Corp | COM | 450,000 | $977.0K | 0.4% | History |
| XFORX4 Pharmaceuticals, Inc | COM | 850,000 | $740.0K | 0.3% | History |
| KZRKezar Life Sciences, Inc. | COM | 175,000 | $548.0K | 0.2% | History |